Peaty uncoupler vs. Ozempic who wins ? New study.
-
@alfredoolivas nice thanks for the update.
I might actually do this. -
@alfredoolivas I ordered BAM15 a few days ago and if the tracking info is correct , it will arrive tomorrow already.
Not sure if I'll have time to try it right away since I'm still running another experiment, but maybe over the weekend I'll try a low dose.
Dare to think.
My X:
x.com/Metabolicmonstr -
@Mauritio yeah it’s a crazy shipping line they have running.
Are you referring to the DNP microdose? Amazing experimentation, may I ask what inspired you to pick 2mg as a dose or where I can find an explanation you previously gave?
-
@alfredoolivas Yes, you can find more on my X. Search for "DNP" on my site or look at my latest post on DNP in which I quoted a few other posts on low dose DNP (including the relevant studies). And there's more studies on microdose DNP that I haven't postet yet. One study shows reversal of ALS phenotype in mice for example.
I suspect that I've developed tolerance to the 2mg dose. So I'll probably increase the dose to 4mg and see if the benefits reappear.
-
Interesting thread @onliest
-
I received my BAM15 today (finally).
If someone wants to purchase half of it, let me know. -
Here BAM15 alleviated atherosclerosis by inhibiting the NLRP3 inflammosome.
The dosage was only 30mg (HED), so it seems low doses have benefits as well.
This was subcutaneous injectiom so you have to factor that in"BAM15 reduced atherosclerotic plaque formation, lipid deposition, and inflammation, and diminished mtROS expression and ox-mtDNA content in the AS mouse models. In both in vivo and in vitro experiments, BAM15 markedly inhibited the activation of the NLRP3 inflammasome, leading to reduced pyroptosis in endothelial cells. "
https://pubmed.ncbi.nlm.nih.gov/40393254/Here, BAM15 and a Trb agonist are more effective for treating fatty liver than each on their own. So combining BAM with sobetirome or just T3 should be good combo for the liver .
https://pubmed.ncbi.nlm.nih.gov/39152636/ -
@Mauritio said in Peaty uncoupler vs. Ozempic who wins ? New study.:
BAM down regulated SCD1 by almost 900-fold ! SCD1 concerts saturated fats into unsaturated fats and is implicated in many chronic diseases.
"...severe downregulation of sterol regulatory element‐binding transcription factor 1 (Srebf1 ; 490‐fold downregulated), carbohydrate‐responsive element‐binding protein (Mlxlpl ; 99‐fold downregulated), fatty acid synthase (Fasn ; 89‐fold downregulated), stearoyl‐CoA desaturase (Scd1 ; 898‐fold downregulated), adipose triglyceride lipase (Pnpla2 ; undetected in BAM15), and peroxisome proliferator‐activated receptor gamma (Pparg ; undetected in BAM15)”
I think this above part is very interesting. These down regulated factors all point to BAM lowering lipogenesis. It might even all be downstream from PPARg .
Fireinabottle writes about it here . Animals that lack PPARg remain insulin sensitive on a high PUFA diet and gain less weight. This happens because PPARg increased PDK4 which lowers pyruvate dehydrogenase. So lowering it will increase pyruvate dehydrogenase and enable you to burn sugar better.
In the study above on BAM15, PPARg was undetectable. -
I've seen people dose BAM15 several times a day due to its short half life, but this might not be necessary.
Since it's fat soluble, it stays active inside the mitochondria for a longer period of time.
On its safety:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7338798/#emmm202012088-fig-0005ev
Dare to think.
My X:
x.com/Metabolicmonstr -
@Mauritio I wish the intracellular half life of substances was studied more
